Physician-scientist developing microbiome-based therapies to combat antimicrobial resistance and improve health. I lead clinical trials of fecal microbiota transplantation, direct a stool donor program, and integrate metagenomics with clinical research to move from pathogen-focused medicine toward ecologic health.
Associate Professor of Medicine, Division of Infectious Diseases. Medical Director, Microbiome Enrichment Program Stool Donor Program. Sponsor-Investigator for FDA-authorized FMT clinical trials.
Engaged in clinical infectious disease practice and infrastructure development of translational microbiome research in Northern New England.
Randomized controlled trial of FMT for multidrug-resistant organism decolonization. CDC Prevention Epicenter-funded, FDA IND-authorized.
FMT to reduce antimicrobial-resistant infections. CDC Prevention Epicenter-funded, FDA IND-authorized.
Assessing the impact of antibiotics on the gut microbiome and clinical outcomes in patients admitted to long-term care.
Strain-level (meta)genomic analyses of clinical samples to track compositional and functional dynamics and donor engraftment - within human hosts.
Co-chair of the Prevention Epicenter Microbiome Workgroup defining research priorities for microbiome-infection interactions.
Developing microbiome-derived biomarkers to improve efficiency of trials for patients who are colonized with multidrug-resistant organisms.
Elements supporting the published results from the PREMIX phase 1 randomized controlled trial of FMT in renal transplant recipients colonized by multidrug-resistant organisms.
End-to-end experience as Sponsor-Investigator across multiple FDA IND-authorized trials of fecal microbiota transplantation.
IND applications, amendments, protocol development, and ongoing FDA correspondence for investigational microbiome products.
Donor screening, product manufacturing, stability testing, and quality systems for investigational FMT products.
Metagenomics, strain-level engraftment analysis, and biomarker development for live biotherapeutic products.